DNMT inhibitors such as azacytidine, decitabine, and the DNMT1-selective inhibitor GSK3482364 have demonstrated therapeutic potential in β-hemoglobinopathies by inducing γ-globin expression through promoter hypomethylation, as shown in patients with β-thalassemia and SCD as well as in transgenic SCD mouse models [231,232,233,234]. The gene discussed is DNMT1; the disease is Schnyder corneal dystrophy.